• Medycyna
  • 22 kwietnia
  • FDA to approve Grace Therapeutics' GTx-104
    2
  • FDA to approve Sanofi's Subcutaneous Sarclisa
    2
  • 26 kwietnia
  • FDA to approve Sanofi's Dupixent
    2
  • 28 kwietnia
  • FDA to approve Sanofi's Tzield
    2
  • 29 kwietnia
  • FDA to approve AstraZeneca's Camizestrant
    2
  • FDA to approve Axsome Therapeutics AXS-05
    2
  • 30 grudnia
  • CDC to issue Level 3 warning by December 31
    2
  • CDC to issue Level 4 warning by December 31
    2
  • FDA approves Retatrutide this year?
    2

mp